Trial Profile

An Open-label, Multi-center, Dose-escalation and Expansion, Phase 1/2a Study to Evaluate the Safety, Tolerability, PK/PD, and Preliminary Anti-tumor Activity of GIC-102 Monotherapy in Patients With Advanced Solid Tumors, R/R Non-Hodgkin Lymphoma, and Multiple Myeloma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 18 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GIC-102 (Primary) ; Cyclophosphamide; Fludarabine
Indications Colorectal cancer; Haematological malignancies; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
Focus Adverse reactions; First in man
Sponsors GICELL

09 Jul 2024 Phase has been changed to I\II ,no of patients has been increased ,addition of ORR to the primary endpoinnt
09 Jul 2024 Planned number of patients changed from 9 to 50.
04 Jun 2024 Results (n=6 as of 31 Dec, 2023)presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com